



Date June 17, 2026

Page 01 | 03

UPDATE

Boehringer Ingelheim (Boehringer) is updating its 340B Program Policies

Notice to 340B Covered Entities: Effective July 6, 2026

Boehringer strongly supports the original intent of the 340B program and remains committed to its mission of expanding patient access to essential medications for the patients we serve today and into the future. However, we are concerned about well-documented integrity and oversight issues that have caused the program to drift from its original intent. Limited transparency around 340B-eligible prescriptions and profit flows within the supply chain undermines the program's effectiveness.

Our policies aim to reinforce the program's core purpose—ensuring vulnerable and uninsured patients benefit directly from its resources. We believe the initiatives we are detailing in our policies will further strengthen the program and support its core mission to ensure patients have access to the medications they need.

Please take notice that Boehringer is updating its 340B program claims collection policy. **Effective July 6, 2026, Boehringer will require the submission of pharmacy and medical claims data on 340B utilization filled at in-house pharmacies for all covered entity types.** All specified claims data must be submitted on the 340B ESP™ platform within 45 days of the date of dispense. Failure to provide timely, complete, and accurate data for products dispensed at the 340B price may result in loss of access to 340B pricing until the required data is provided.

The submission of claims data on 340B utilization filled at in-house pharmacies expands on our existing 340B program contract pharmacy claims collection policy. Boehringer requires all covered entity types to submit claims data for all 340B dispenses including in-house and contract pharmacy dispenses. Covered entities who are not currently submitting claims data can do so by registering at www.340BESP.com.

The FAQs below provide additional information on Boehringer's 340B policy. If you have any questions regarding Boehringer's updated 340B Program claims collection policy, please reach out to support@340besp.com.

Best regards,

DocuSigned by:

20828E4D4469469...

Christine G. Marsh
Senior Vice President, Value and Access
Boehringer Ingelheim Pharmaceuticals, Inc.

Life forward

Frequently Asked Questions

340B Program In-House Claims Collection Policy

Q: What types of covered entities are included in Boehringer's 340B Program Policy?

A: All 340B covered entities (hospital and federal grantee) are subject to Boehringer's Policy.

Q: Which products are subject to Boehringer's in-house claims collection policy?

A: Boehringer's policy applies to all products listed in [Exhibit A](#).

Q: What is an in-house (entity-owned') pharmacy?

A: An in-house ('entity-owned') pharmacy is a pharmacy that is owned by the 340B covered entity and listed in HRSA OPAIS as "Street Address" and "Shipping Addresses." If Boehringer identifies that a covered entity is shipping 340B priced product to a street address or shipping address(es) location for the covered entity as listed in HRSA OPAIS and to a contract pharmacy location(s), Boehringer will notify the covered entity in these instances. Covered entities may continue to access the 340B price at the locations listed on HRSA OPAIS as registered street address or shipping address(es).

Q: What are the requirements for submission of 340B claims data?

A: Boehringer is utilizing Second Sight Solutions' 340B ESP™ platform (www.340Besp.com) to support claims collection on behalf of all entity types. Claims data must be submitted within forty-five (45) days of the date of dispense for the covered entity to continue to access 340B pricing for all Boehringer products in [Exhibit A](#). Please see 340B ESP™ for additional details on submitting claims data, including the limited set of required data fields.

Q: My Covered Entity currently submits claims to the 340B ESP platform for contract pharmacies. Does my Covered Entity now have to submit claims for dispenses at my in-house pharmacy(s)?

A: Yes, effective July 6, 2026, covered entities are required to submit pharmacy and medical claims data on 340B utilization filled at covered entities in-house pharmacies.

Q: Are there any changes to Boehringer's contract pharmacy claims submission policy?

A: No, covered entities that do not have an in-house pharmacy and have a designated contract pharmacy, have been required to submit claims data since December 2, 2024. The claims collection policy for contract pharmacy(s) remains unchanged.

Q: Does Boehringer's 340B In-House Claims Collection Policy apply to covered entities in all states?

A: Boehringer's 340B In-House Claims Collection Policy applies to covered entities in states where applicable by state law. Existing state carve-out exemptions that apply to Boehringer 340B Program Claims Collection Policy (applicable to contract pharmacy claims collection) are unaffected by this notice and will also apply to Boehringer's In-House Claims Collection Policy. For any future state changes, entities in affected states will be notified through separate communications, for specific state actions.

Exhibit A

ADALIMUMAB-ADBIM[®]

APTIVUS[®]

ATROVENT[®]

COMBIVENT[®]RESPIMAT[®]

CYLTEZO[®]

GLYXAMBI[®]

JARDIANCE[®]

JENTADUETO[®]

JENTADUETO XR[®]

MICARDIS[®]

MICARDIS HCT[®]

OFEV[®]

PRADAXA[®]

SPIRIVA[®] HandiHaler[®]

SPIRIVA[®] RESPIMAT[®]

STIOLTO[®] RESPIMAT[®]

STRIVERDI[®] RESPIMAT[®]

SYNJARDY[®]

SYNJARDY XR[®]

TRADJENTA[®]

TRIJARDY XR[®]

VIRAMUNE XR[®]